InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
2
Disclosed sells
0
T+90 hit rate
100%
T+90 mean return
+43.7%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by Caffo Nathan, Directeur Commercial. Director active across 1 company, notably Candel Therapeutics, Inc.. In total, 2 filings have been recorded. Split: 2 buys · 0 sell. Total volume traded: €81k. Activity tracked since 29 July 2021. The latest transaction was filed on 29 July 2021 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.
Declarations2 total
6,000 shares@ US$8.0050.0% of flowCommon StockSEC:0000899243-21-031086
Ideal exit: 25 Apr 2022 (T+270)
6,000 shares@ US$8.000.013% mcap50.0% of flowCommon StockSEC:0000899243-21-031086:0
Ideal exit: 25 Apr 2022 (T+270)
2 of 2 declarations
About Caffo Nathan
Caffo Nathan is the Chief Business Officer at Candel Therapeutics, Inc. In this role, he is responsible for business strategy and partnership development. His expertise in the biopharmaceutical sector enables him to guide the company towards sustainable growth. Nathan works closely with teams to align business initiatives with strategic objectives.
